argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
547.60
+0.42 (0.08%)
At close: Jul 2, 2025
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
$1,652,947
Profits / Employee
$665,482
Market Cap
33.32B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| American Oncology Network | 1,914 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
argenx SE News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX - PRNewsWire
- 7 days ago - Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years - Benzinga
- 9 days ago - Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin - Seeking Alpha
- 9 days ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 9 days ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 9 days ago - argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo - Seeking Alpha
- 19 days ago - argenx gets EU nod for Vyvgart subcutaneous injection - Seeking Alpha
- 19 days ago - argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire